This Branded Generics Stock Rises 185% in 3 Years: How a Debt Clean-Up and a Big Pharma Deal Powered It
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
CMP around Rs 2,415 (10 Sep 2026). 3-year return 184.50%. 52W range Rs 1,792.60 to Rs 2,537.60. Market cap Rs 68,850 Cr. Q1 FY27 PAT approx Rs 483 Cr vs Rs 47 Cr.
Quick Answer
Glenmark Pharmaceuticals is the branded generics stock behind a return of approximately 184.50% in three years. The share rose from around Rs 849 to near Rs 2,415 as the company repaid debt, cleared USFDA hurdles and earned a USD 700 million upfront payment from AbbVie. The 1-year return is a slower 24.14%, and brokerage targets range from Rs 2,100 to Rs 2,590.
This branded generics stock has nearly tripled investor money in three years, turning Rs 1 lakh into roughly Rs 2.85 lakh. One Mumbai-based drug maker delivered a 3-year return of 184.50% as of 10 September 2026, ranking 22nd in a screen of 101 large-cap and mid-cap NSE shares.
The company is Glenmark Pharmaceuticals Ltd (NSE: GLENMARK), a research-led maker of branded generic medicines for India and emerging markets, with a sizeable US, European and innovative drug business. The Glenmark Pharma share price has climbed from around Rs 849 three years ago to approximately Rs 2,415 on 10 September 2026, and the company is now valued at approximately Rs 68,850 crore.
Click Here – Get Free Investment Predictions
Which Branded Generics Stock Rose 185% in 3 Years?
Glenmark Pharma is the branded generics stock that rose approximately 185% in three years, placing it 22nd out of 101 screened NSE stocks. The Glenmark Pharma share price closed near Rs 2,415 on 10 September 2026, down about 0.8% from the previous close of Rs 2,435.
The share trades around 5% below its 52-week high of Rs 2,537.60 and roughly 35% above its 52-week low of Rs 1,792.60. Its daily volume of roughly 2.6 lakh shares shows the share remains actively traded. Here is how this branded generics stock has performed across time frames in our screen:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 6.51% | 35 |
| 6 Months | 11.20% | 79 |
| 1 Year | 24.14% | 56 |
| 3 Years | 184.50% | 22 |
| 5 Years | 376.34% | 25 |
Returns are simple price changes and are not annualised. Glenmark has a face value of Rs 1 per share and did not carry out any stock split or bonus issue in the three-year window, so the 184.50% figure for this branded generics stock reflects genuine price appreciation.
The table also shows how the pace has changed. Most of the gains in this branded generics stock came in 2023 and 2024, when the share roughly doubled in each calendar year. The 1-year return is a more modest 24.14%, and the 6-month rank of 79 shows the rally has slowed sharply in 2026.
Why Did This Branded Generics Stock Rise 185% in 3 Years?
This branded generics stock rose approximately 185% because Glenmark fixed its balance sheet, cleared key US regulatory hurdles and then monetised its innovative drug pipeline. For a branded generics stock, that mix of balance sheet repair and pipeline value is unusual. The early part of the rally was a turnaround story, while the later part was driven by a large licensing deal and record profits.
1. Debt Clean-Up Through the Glenmark Life Sciences Sale
In September 2023, Glenmark agreed to sell a 75% stake in its API arm, Glenmark Life Sciences, to Nirma for approximately Rs 5,651 crore. The deal was completed in March 2024 and the cash was used to repay most of the group’s borrowings.
Debt to equity fell from 0.55 in FY22 to 0.16 by FY26, and management now reports a zero gross debt position. For a branded generics stock that the market had long discounted for its heavy borrowings, this reset changed how investors valued the business.
2. US Regulatory Relief and a Stronger Core Business
The accounting loss of approximately Rs 1,831 crore in FY24 was linked to the stake sale and one-time items, not a collapse in operations. Investors looked through it as core margins improved and US compliance issues eased.
A key example came in September 2024, when a USFDA inspection at the Aurangabad formulation plant ended with a Form 483 carrying zero observations. The branded generics stock rose around 9% in a single session to approximately Rs 1,764 on that news, as a clean inspection opened the door to more US launches.
3. The USD 700 Million AbbVie Licensing Deal
In July 2025, Glenmark’s innovation arm, Ichnos Glenmark Innovation, licensed its multiple myeloma drug candidate ISB 2001 to AbbVie for markets including North America, Europe, Japan and Greater China. Glenmark received an upfront payment of USD 700 million, approximately Rs 6,000 crore, in September 2025.
The agreement also carries up to USD 1.2 billion in potential milestone payments, plus royalties. The deal pushed the Glenmark Pharma share price to a record high and gave the market proof that the company’s research spending can create real value, a rare feature for a branded generics stock.
4. Brand Building in India and Emerging Markets
India remains the anchor. In Q1 FY27, India formulation revenue grew 15.5% to approximately Rs 1,432 crore, while secondary sales rose 18.1%. Emerging markets grew 27.7%, and the India consumer care business rose 28%.
The respiratory brand Ryaltris is now present in 57 markets, with secondary sales growing more than 40% year on year. Oncology in-licensed brands Tevimbra and Brukinsa crossed Rs 100 crore in their first twelve months in India. These steady, prescription-led franchises are the reason investors treat Glenmark as a branded generics stock rather than a pure US commodity play.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Glenmark Pharma Share Price and Financial Performance
Profits have recovered sharply. FY26 revenue rose to approximately Rs 17,443 crore from Rs 13,435 crore in FY25, while net profit climbed to around Rs 1,362 crore from Rs 1,047 crore, the best annual profit this branded generics stock has reported in the five years shown. The FY26 numbers include the one-time AbbVie upfront income booked mainly in the September 2025 quarter.
| Metric (Rs Cr) | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 3,291 | 6,248 | 3,945 | 3,960 | 4,084 |
| EBITDA | 607 | 2,560 | 914 | 952 | 871 |
| Net Profit | 47 | 610 | 403 | 301 | 483 |
| Net Margin | 8.52% | 25.57% | 13.89% | 14.96% | 12.28% |
| EPS (Rs) | 1.66 | 21.62 | 14.28 | 10.68 | 17.11 |
Revenue includes other income. The September 2025 quarter is inflated by the AbbVie payment, so the cleaner comparison is Q1 FY27 against Q1 FY26. On that basis, the branded generics stock grew net profit roughly ten times to approximately Rs 483 crore from Rs 47 crore.
For Q1 FY27, reported revenue from operations was approximately Rs 4,018 crore, up 23.1% year on year, and core growth excluding deferred ISB 2001 income was around 18%. EBITDA margin was about 20%, and management kept its FY27 operating margin guidance at 21% to 22%. Cash flow also turned strong, with FY26 operating cash flow of approximately Rs 3,445 crore after two weak years, which gives this branded generics stock room to fund capex of around Rs 1,358 crore without new borrowing.
Valuation of This Branded Generics Stock
At current levels, this branded generics stock trades at a PE of approximately 38.3, almost in line with the industry PE of 38.26. The price to book ratio is about 6.55, return on equity is around 28%, and debt to equity stands at a low 0.06.
The branded generics stock therefore no longer trades at the steep discount it carried three years ago. With profits partly boosted by one-time licensing income, investors should judge valuation on recurring earnings rather than the headline trailing number.
Who Owns This Branded Generics Stock?
Promoters have held a steady 46.65% stake in this branded generics stock throughout the period, with no dilution. The bigger shift is between foreign and domestic institutions.
| Holder | Dec 2024 | Jun 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs | 23.50% | 20.60% | 19.20% | 20.89% |
| Mutual Funds | 12.12% | 15.55% | 17.86% | 16.76% |
| Retail and Others | 16.00% | 15.10% | 14.00% | 13.82% |
Mutual fund holding rose from about 12% to nearly 18% through 2025 as domestic funds bought into the turnaround of this branded generics stock, while foreign investors trimmed their stake. In 2026, FII holding has edged back up to around 20.9% and mutual funds have booked some profit, which matches the flatter move in this branded generics stock during 2026.
Several healthcare and multi-cap mutual fund schemes hold the share, and sector funds allocate around 2% of their assets to it. Falling retail ownership also suggests the branded generics stock is now held mostly by long-term institutions.
Key Risks for This Branded Generics Stock
The biggest risk is a tough base. FY26 profits included the AbbVie upfront payment, so FY27 reported growth will look weak, and one domestic brokerage expects North America growth to moderate this year.
Other risks include:
Cost pressure: Management flagged that geopolitical tensions are raising API and logistics costs, which could squeeze gross margins of the branded generics stock.
US regulatory exposure: Glenmark has had several USFDA observations and warning letters at its plants in the past. Any fresh adverse inspection could delay US launches.
Pipeline dependence: Future milestone income from ISB 2001 depends on clinical success in AbbVie’s hands. A trial setback would hurt sentiment around this branded generics stock.
Slower Europe: For a branded generics stock with a big European franchise, this matters. Management expects Europe growth to slow to high single digits in FY27 as the portfolio is reshaped.
Valuation: A PE near 38 leaves less room for error than three years ago, and the weak 6-month rank shows momentum has faded.
Download the Univest iOS App or Univest Android App to track the Glenmark Pharma share price live
Glenmark Pharma Share: Analyst View
Analyst opinion on this branded generics stock is split after the Q1 FY27 results. Brokerages covering the branded generics stock broadly agree the India business and pipeline are strong, but they differ on how much of that is already priced in after a near threefold rise.
Glenmark Pharma Share Price Target
After the Q1 FY27 results in August 2026, a domestic brokerage kept a buy rating with a Glenmark Pharma share price target of Rs 2,590. It expects revenue to grow at around 10.6% a year through FY29, led by mid-teens India growth, and sees stronger growth from FY28 once investments normalise.
Another domestic brokerage holds a more cautious view, with a hold rating and a Glenmark Pharma share price target of Rs 2,100. It values the company at 20 times estimated FY28 earnings plus around Rs 225 per share for its new chemical entity pipeline.
With the share near Rs 2,415, the higher target implies upside of approximately 7%, while the lower one is about 13% below current levels. Key things to watch are FY27 margin delivery, US product launches and progress in the innovative drug pipeline of this branded generics stock.
Conclusion
Glenmark Pharma has turned from a debt-laden laggard into a leaner branded generics stock, and one of the better compounders in our screen, with a 3-year return of 184.50%. Debt repayment, cleaner US inspections, steady India growth and the AbbVie licensing deal together explain why this branded generics stock nearly tripled.
The recent picture is more measured. The 1-year return is 24.14%, valuations have caught up with the sector, and FY27 growth faces a high base. Investors tracking the Glenmark Pharma share price may want to watch recurring margins and pipeline milestones rather than the headline rally before taking a view on this branded generics stock.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which branded generics stock rose 185% in 3 years?
Ans. Glenmark Pharmaceuticals (NSE: GLENMARK) is the branded generics stock that gained approximately 184.50% over three years as of 10 September 2026. It ranked 22nd among 101 large-cap and mid-cap NSE stocks in our screen.
Why did the Glenmark Pharma share price rise so much?
Ans. The rise came from a debt clean-up after selling a 75% stake in Glenmark Life Sciences, cleaner USFDA inspections, steady India growth and a USD 700 million upfront payment from AbbVie for ISB 2001. Profits recovered from a loss in FY24 to around Rs 1,362 crore in FY26.
What is the Glenmark Pharma share price target?
Ans. After Q1 FY27 results, one domestic brokerage set a Glenmark Pharma share price target of Rs 2,590 with a buy rating, while another has a hold rating with a target of Rs 2,100. The share trades near Rs 2,415.
Was the 185% return affected by a stock split or bonus?
Ans. No. Glenmark did not issue bonus shares or split its stock during the three-year period, so the return reflects genuine price appreciation.
How did Glenmark perform in Q1 FY27?
Ans. The branded generics stock posted strong numbers. Revenue from operations rose 23.1% to approximately Rs 4,018 crore and net profit was around Rs 483 crore against Rs 47 crore a year earlier. North America grew 41.1% and India formulations grew 15.5%.
Is Glenmark Pharma debt free?
Ans. Yes, on a gross basis. Management reports a zero gross debt position after using the Glenmark Life Sciences sale proceeds and AbbVie income to repay borrowings. Debt to equity is around 0.06.
What are the risks in this branded generics stock?
Ans. Key risks include a high FY27 base due to one-time AbbVie income, rising API and logistics costs, USFDA inspection outcomes and dependence on clinical success of ISB 2001. A PE near 38 also leaves less room for error in this branded generics stock.
How has the Glenmark Pharma share performed in the last year?
Ans. The share gained approximately 24.14% in one year and 11.2% in six months, much slower than its 3-year pace. It trades around 5% below its 52-week high of Rs 2,537.60.
